PureTech Health plc

PRTC

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
PRTC
CIK0001782999
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address6 TIDE STREET, SUITE 400, BOSTON, MA, 02210
Website puretechhealth.com
Phone617-482-2333
CEODaphne Zohar
Employees100

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$47.64 million
Pre-Tax Income$322.23 million
Net Income$326.24 million
Net Income to Common$274.78 million
EPS$0.21
View All
Balance Sheet
Cash$280.64 million
Assets$602.64 million
Liabilities$194.70 million
Common Equity$124.44 million
Liabilities & Equity$602.64 million
View All
Cash Flow Statement
Calculations
NOPAT$177.84 million
EBITDA$331.03 million
Price to Earnings$1.52
Price to Book$3.35
ROE75.33%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

BOSTON, May 09, 2025--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

Article Link

Shareholders In PureTech Health (LON:PRTC) Should Look Beyond Earnings For The Full Story

Even though PureTech Health plc ( LON:PRTC ) posted strong earnings recently, the stock hasn't reacted in a large way...

Article Link

PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and ...

PureTech Health PLC (PTCHF) reports robust cash position, successful clinical trials, and strategic monetization, despite market valuation challenges.

Article Link

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

BOSTON, May 01, 2025--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

Article Link

PureTech Announces Annual Results for Year Ended December 31, 2024

BOSTON, April 30, 2025--PureTech Announces Annual Results for Year Ended December 31, 2024

Article Link